New Validated Stability Indicating RP-HPLC Method for Simultaneous Estimation of Metformin and Alogliptin in Human Plasma

Ashutosh KS¹, Manidipa D², Seshagiri RJVLN² and Gowri SD⁴

¹Department of Pharmaceutical Analysis and Quality Assurance, AKRG College of Pharmacy, Nallajerla, West Godavari, Andhra Pradesh, India
²Department of Pharmaceutics, AKRG College of Pharmacy, Nallajerla, West Godavari, Andhra Pradesh, India
³Srinivasarao College of Pharmacy, Pothinenimallayapalem, Madhurawada, Visakhapatnam, Andhra Pradesh, India
⁴College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India

Abstract

A validated new stability indicating RP-HPLC method for the quantitative determination of metformin and alogliptin in human plasma was developed as per US-FDA guidelines. The drug was spiked in the plasma and extracted with mobile phase by precipitation method. The extracted analyte was injected into X-Terra C18 (4.6 × 150 mm, 3.5 µm, Make: ACE) or equivalent, maintained at 25°C temperature and effluent was monitored at 235 nm. The mobile phase was consisted of sodium dihydrogen ortho phosphate [pH 4.0]:acetoni trite [HPLC Grade] (70:30 v/v). The flow rate was maintained at 1.0 mL/min. The calibration curve for metformin and alogliptin was linear from 300.0 to 700.0 µg/mL (r²=0.997) and 7.5 to 17.5 µg/mL (r²=0.998) respectively. The inter-day and intra-day precision was found to be within limits. The average % recovery for metformin and alogliptin were 100.17 and 99.40-99.55% respectively and reproducibility was found to be satisfactory. This RP-HPLC method is suitable for determining the concentration of metformin and alogliptin in human plasma and it can be applied for routine analysis for determination of the metformin and alogliptin from dosage form during pharmaco kinetic study.

Keywords: Metformin; Alogliptin; RP-HPLC; ICH-guidelines; Validation; Human Plasma; US-FDA guidelines

Introduction

Diabetes is a chronic condition associated with abnormally high levels of sugar (glucose) in the blood. The production of insulin by the pancreas lowers blood glucose level. Due to the absence or insufficient production of insulin causes diabetes. There are two types of diabetes which are referred to as type 1 and type 2 [1]. Formerly names for these conditions were insulin-dependent and non-insulin-dependent diabetes, or juvenile onset and adult onset diabetes. The symptoms of diabetes include increased urine output, thirst, hunger, and fatigue. Diabetes is diagnosed by blood sugar (glucose) testing. The number of individuals affected by diabetes is continuing to increase worldwide; the need for effective management assumes ever greater urgency [2]. Newer classes of medications, particularly those which work via the incretin pathway, achieve glucose lowering and minimizing risks associated with more traditional therapies. Ideally, combination therapies should be well tolerated, convenient to take, have few contraindications, have a low risk of hypoglycemia and weight gain, and be reasonably effective over both the short and long term such as the combination of metformin (MF) and the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALG). The chemical structure of metformin and alogliptin were represented in Figures 1 and 2 respectively. Alogliptin [3-5] is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors represent a new therapeutic approach to the treatment of type 2 diabetes that functions to stimulate glucose dependent insulin release and reduce glucagon levels. This is done through inhibition of the inactivation of in cretins, particularly glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretin glucose-dependent insulin tropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1), thereby improving glycemic control [3-5]. Metformin hydrochloride (MTF) [6-9] (C₆H₁₁N,HCl) is 1:1 dimethylbiguanide monohydrochloride is an anti-diabetic drug from the biguanide class of Oral Hypoglycaemic agents, given orally in the treatment of non-insulin-dependent diabetes mellitus. The main action of Metformin HCl is in increasing glucose transport across the cell membrane in skeletal muscle. Several analytical methods based on UV [9,10], Spectrofluorimetry [11,12], Reverse Phase-HPLC [13-23], LC-MS/MS [24-27], HPTLC [28] were reported for the determination of metformin either in alone or in combination with other drugs. Although literature survey reveals that no methods were reported for metformin (MTF) and alogliptin (ALG) in combination form.

Materials and Methods

Chernicals and reagents

The reference sample of metformin and alogliptin were supplied by M/s Pharma Train, Hyderabad. HPLC grade water (prepared by using 0.45 Millipore Milli-Q) was procured from Standard Reagents, Hyderabad. HPLC grade acetonitrile was purchased from Merck, Mumbai. The chemicals used for preparation of buffer include sodium dihydrogen ortho phosphate (Finar Chemicals, Ahmedabad), and orthophosphoric acid (Standard Reagents, Hyderabad). 0.45 µm membrane filters (Advanced Micro Devices Pvt. Ltd., Chandigarh, India) were used for filtration of various solvents and solutions intended for injection into the column [29-32].

*Corresponding author: Ashutosh Kumar S, Department of Pharmaceutical Analysis and Quality Assurance, AKRG College of Pharmacy, Nallajerla, West Godavari, Andhra Pradesh-534 112, India, Tel: 08818277997; Fax: 08818277997, E-mail: ashu.mpharm2007@gmail.com

Received August 26, 2015; Accepted September 02, 2015; Published Setember 12, 2015

Citation: Ashutosh KS, Manidipa D, Seshagiri RJVLN, Gowri SD (2015) New Validated Stability Indicating RP-HPLC Method for Simultaneous Estimation of Metformin and Alogliptin in Human Plasma. J Chromatogr Sep Tech 6: 293. doi:10.4172/2157-7064.1000293

Copyright: © 2015 Ashutosh KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Instrumentation

A Waters Alliance 2695 separation module equipped with a 2487 UV detector was employed throughout this study. Column that was employed in the method was X-Terra C_18 (4.6 x 150 mm, 3.5 µm, Make: ACE). The samples were injected with an automatic injector. The 20 µL volume of sample was injected. The input and output operations of the chromatographic system were monitored by Waters Empower software. The flow rate selected was 1.0 mL per min. The detection was done at 235 nm. The temperature and run time was monitored at 25°C.

Preparation of mobile phase

The mobile phase was prepared by mixing 700 mL phosphate buffer (pH 4.0) and 300 mL of acetonitrile in a 1000 mL clean and dry flask. The resultant mobile phase was filtered through a 0.45 µm membrane filter (Advanced Micro Devices Pvt. Ltd., Chandigarh, India) under vacuum. The resultant mobile phase was degassed in an ultrasonic sonicator for 5 min.

Preparation of diluent

The diluent was prepared by mixing phosphate buffer (pH 4.0) and acetonitrile (HPLC grade) in the ratio of 70:30 v/v. This solution was used to dilute the drug solutions in the study.

Preparation of standard solution of metformin and alogliptin

10 mg metformin was weighed accurately and transferred into a 10 mL clean and dry volumetric flask. Initially, the drug was mixed with 7 mL of diluent. The solution was sonicated for 15 min for complete dissolution of the drug. The final volume was made up to the mark with the same solvent. Similarly, about 10 mg alogliptin was weighed accurately and transferred into a 100 mL clean and dry volumetric flask. Initially, the drug was mixed with 70 mL of diluent. The solution was sonicated for 15 min for complete dissolution of the drug. The final volume was made up to the mark with the same solvent. From the above prepared stock solutions 5.0 mL of metformin and 1.25 mL of alogliptin were pipetted out into a 10 mL clean and dry volumetric flask and it was diluted up to the mark with diluent. This mixed stock solution contains 500.0 µg/mL of metformin and 12.5 µg/mL of alogliptin.

Spiking of metformin and alogliptin into plasma and their extraction from plasma (By precipitation method)

From the above prepared mixed stock solution (500.0 µg/mL of metformin and 12.5 µg/mL of alogliptin), 0.5 mL was pipetted out and spiked into 0.5 mL of plasma in a polypropylene tube (Tosrion’s). Then the tube was cyclo mixed for 5 min. Then 1.0 mL of acetonitrile was added to the tube and centrifuged for 20 min at 3000 rpm. Further the supernatant liquids were collected in another Eppendorf tube and 20 µL supernatant was injected into the analytical column.

Validation Development

Selectivity

An aqueous mixture of metformin and alogliptin (500.0 µg/mL of metformin and 12.5 µg/mL of alogliptin) was prepared and injected into the column and the retention times were checked and any interference at the retention times was checked by comparing the response in the blank. No interference was observed at the retention times for metformin and alogliptin extracted from plasma [33-38]. The method was found to be precise and specific. A typical chromatogram of metformin and alogliptin in plasma is shown in Figure 3.

Sensitivity

To determine the sensitivity in terms of LLOQ, ‘Lower Limit of Quantification’ where the response of LLOQ must be at least five times greater than the response of interference in blank matrix at the retention time of the analyte(s). The LLOQ obtained by the proposed

Preparation of sodium phosphate buffer (pH 4.0)

The buffer solution was prepared by dissolving 2.5 g of sodium dihydrogen ortho phosphate in 900 mL of HPLC grade water in a 1000 mL clean and dry flask. The mixture was stirred well until complete dissolution of the salt. The volume was made up to the mark with water. The pH was adjusted to 4.0 with 1% ortho phosphoric acid.
method were 5.936 and 1.983 µg/mL for metformin and alogliptin respectively.

**Precision**

To check the intra and inter-day variations of the method, solutions containing 500.0 µg/mL of metformin and 12.5 µg/mL of alogliptin were subjected to the proposed HPLC method of analysis and results obtained were noted. The precision of the proposed method i.e., the intra and inter-day variations in the peak areas of the drugs solutions in plasma were calculated in terms of percent relative standard deviation (RSD) and the results are represented in Tables 1, 2, 3 and 4. A statistical evaluation revealed that the percentage relative standard deviation of the drugs at linearity level for 6 injections was less than 2.0. Typical chromatogram of metformin and alogliptin in plasma for intra and inter-day precision are shown in Figures 4 and 5.

**Accuracy**

To determine the accuracy of the proposed method, recovery studies were carried out by analyzing (8.0, 10.0, 12.0 µg/mL of metformin and alogliptin) of pure drugs. The solutions were suitably diluted at linearity level (500.0 µg/mL of metformin and 12.5 µg/mL of alogliptin). Then each dilution was injected thrice (n=3). The percent recoveries of the drugs were determined. The results are shown in Tables 5 and 6.

**Linearity**

In order to find out the linearity range of the proposed HPLC method in plasma, curves were constructed by plotting peak areas obtained for the analyte against their concentrations. A good linear relationship (r²=0.997) was observed between the concentrations of metformin and alogliptin and their corresponding peak areas. The relevant regression equations were y=1192.x-38173 for metformin (r²=0.997) and y=2802x-1113 for alogliptin (r²=0.998) (where y is the peak area and x is the concentration of metformin and alogliptin (µg/mL)). The slope, intercept and the correlation coefficient of the plots are shown in Tables 7 and 8. The linearity ranges for metformin and alogliptin and their corresponding graphs are shown in Figures 6 and 7.

### Table 1: Intra-day precision of the proposed method for Metformin in plasma.

| Injection | Retention Time | Area     |
|-----------|----------------|----------|
| Injection-1 | 2.734          | 553001   |
| Injection-2 | 2.731          | 559476   |
| Injection-3 | 2.738          | 559994   |
| Injection-4 | 2.738          | 552953   |
| Injection-5 | 2.731          | 553012   |
| Injection-6 | 2.732          | 553032   |
| Average    | 2.734          | 554245   |
| Standard Deviation | 0.003         | 2593.64  |
| %RSD       | 0.12           | 0.47     |

### Table 2: Intra-day precision of the proposed method for Alogliptin in plasma.

| Injection | Retention Time | Area     |
|-----------|----------------|----------|
| Injection-1 | 4.451          | 34316    |
| Injection-2 | 4.452          | 34431    |
| Injection-3 | 4.454          | 34085    |
| Injection-4 | 4.459          | 34350    |
| Injection-5 | 4.452          | 34814    |
| Injection-6 | 4.456          | 34360    |
| Average    | 4.454          | 34392.7  |
| Standard Deviation | 0.003         | 237.7    |
| %RSD       | 0.076          | 0.7      |

### Table 3: Inter-day precision of the proposed method for Metformin (on three consecutive days n=6) in plasma.

| Days     | Retention Time | Area     |
|----------|----------------|----------|
| Day-1*   | 2.734          | 563116   |
| Day-2*   | 2.736          | 563076   |
| Day-3*   | 2.735          | 561049   |
| Average  | 2.735          | 562414   |
| Standard Deviation | 0.001       | 1182     |
| %RSD     | 0.04           | 0.21     |

### Table 4: Inter-day precision of the proposed method for Alogliptin (on three consecutive days n=6) in plasma.

| Days     | Retention Time | Area     |
|----------|----------------|----------|
| Day-1*   | 4.451          | 33218    |
| Day-2*   | 4.456          | 33876    |
| Day-3*   | 4.451          | 33790    |
| Average  | 4.452          | 33628    |
| Standard Deviation | 0.003       | 358      |
| %RSD     | 0.06           | 1.1      |

### Table 5: Accuracy data of the proposed method for Metformin in plasma.

| Conc. Level | % Recovery | Avg. % Recovery | Amount Recovered (mg) | SD | % RSD |
|-------------|------------|-----------------|-----------------------|----|-------|
| 80%         | 100.05     | 101.17          | 8.0                   | 0.032 | 0.4   |
| 100%        | 100.05     | 101.17          | 10.01                 | 0.036 | 0.36  |
| 120%        | 100.05     | 101.17          | 12.01                 | 0.042 | 0.35  |
| 100%        | 99.88      | 99.99           | 9.99                  | 0.059 | 0.59  |
| 100%        | 99.88      | 99.99           | 10.06                 | 0.040 | 0.40  |
| 120%        | 99.88      | 99.99           | 12.01                 | 0.042 | 0.42  |
| 100%        | 99.88      | 99.99           | 12.15                 | 0.072 | 0.72  |
| 100%        | 99.88      | 99.99           | 12.07                 | 0.072 | 0.72  |

### Table 6: Accuracy data of the proposed method for Alogliptin in plasma.

| Conc. Level | % Recovery | Avg. % Recovery | Amount Recovered (mg) | SD | % RSD |
|-------------|------------|-----------------|-----------------------|----|-------|
| 80%         | 98.48      | 99.55           | 7.78                  | 0.119 | 1.50  |
| 100%        | 98.48      | 99.55           | 9.85                  | 0.146 | 1.46  |
| 120%        | 98.48      | 99.40           | 11.82                 | 0.178 | 1.49  |
| 100%        | 98.48      | 99.55           | 10.12                 | 0.146 | 1.46  |
| 120%        | 98.48      | 99.40           | 11.82                 | 0.178 | 1.49  |
| 100%        | 98.48      | 99.55           | 10.12                 | 0.146 | 1.46  |
| 120%        | 98.48      | 99.40           | 11.82                 | 0.178 | 1.49  |

### Table 7: Linearity range of Metformin in plasma.

| Concentration (µg/mL) | Area     | Statistical Analysis |
|-----------------------|----------|----------------------|
| 300                   | 308855   | Slope=1192 Intercept=-38173 C. C=0.997 |
| 400                   | 445785   |                      |
| 500                   | 564758   |                      |
| 600                   | 684752   |                      |
| 700                   | 785468   |                      |

### Table 8: Linearity range of Alogliptin in plasma.

| Concentration (µg/mL) | Area     | Statistical Analysis |
|-----------------------|----------|----------------------|
| 7.5                   | 19414    | Slope=2802 Intercept=-1113 C. C=0.998 |
| 10                    | 27219    |                      |
| 12.5                  | 34484    |                      |
| 15                    | 40829    |                      |
| 17.5                  | 47634    |                      |
| S. No. | Standard Sample | Freeze and Thaw Stability Sample | Short Term Stability Sample | Long Term Stability Sample |
|-------|----------------|----------------------------------|-----------------------------|---------------------------|
| 1.    | 201585         | 185470                           | 195862                      | 187452                    |
| 2.    | 204758         | 189562                           | 194258                      | 187569                    |
| 3.    | 206984         | 188475                           | 196541                      | 187414                    |
| Mean  | 204442         | 187835.7                         | 195554                      | 187478                    |
| SD    | 2713           | 2120                             | 1172                        | 81                        |
| %RSD  | 1.33           | 1.13                             | 0.60                        | 0.04                      |
| Assay | 91.88          | 95.65                            | 91.70                       |                           |

Table 9: The Stability data for Metformin in plasma.

| S. No. | Standard Sample | Freeze and Thaw Stability Sample | Short Term Stability Sample | Long Term Stability Sample |
|-------|----------------|----------------------------------|-----------------------------|---------------------------|
| 1.    | 13985          | 12014                            | 12956                       | 12014                     |
| 2.    | 13586          | 12036                            | 12947                       | 12036                     |
| 3.    | 13632          | 12159                            | 12933                       | 12159                     |
| Mean  | 13734          | 12069.67                         | 12945                       | 12070                     |
| SD    | 218            | 78                               | 12                          | 78                        |
| %RSD  | 1.59           | 0.65                             | 0.09                        | 0.65                      |
| Assay | 87.88          | 94.26                            | 87.88                       |                           |

Table 10: The Stability result for Alogliptin in plasma.

**Figure 3:** A typical chromatogram of Metformin and Alogliptin standard drugs in plasma.

**Figure 4:** Typical chromatogram of metformin and alogliptin in plasma for intra-day precision.

**Figure 5:** Typical chromatogram of metformin and alogliptin in plasma for inter-day precision.

**Figure 6:** Calibration curve for Metformin in plasma.

\[ y = 1192x - 38173 \]
\[ r^2 = 0.997 \]

**Figure 7:** Calibration curve for Alogliptin in plasma.

\[ y = 2802x - 1113 \]
\[ r^2 = 0.998 \]
Stability

All stability determinations used a set of samples prepared from a freshly made stock solution of the analyte in the appropriate analyte-free, interference-free biological matrix [39]. The stock solutions of the analyte for stability evaluation were prepared in an appropriate solvent at known concentrations. To test the stability of the drug extract, it was subjected to

- Freeze and thaw stability at -20°C ± 2°C,
- Short term stability for period of 24 hours stored at room temperature,
- Long term stability for period of 15 days stored at 4°C.

Similar to the preparation of the standard preparation, the above samples were spiked into the plasma and extracted and collected in vial and injected into HPLC system. All the stability samples compared against the standard stock solution assessed for stability. The results are presented in Tables 9 and 10 (the figures in the table are in peak area units). Typical chromatograms for standard samples, freeze and thaw stability samples, short term stability samples and long term stability samples were represented in Figures 8, 9, 10 and 11.

Results and Discussion

To optimize the mobile phase, various proportions of sodium phosphate buffer (pH 4.0) with acetonitrile (HPLC Grade) were tested. The use of sodium phosphate buffer (pH 4.0) and acetonitrile (HPLC Grade) in the ratio of 70:30 v/v resulted in peak with good shapes and resolution. A flow rate of 1.0 mL/min was found to be optimum in the 0.4-1.5 mL/min range resulting in short retention time, baseline stability and minimum noise.

The LLOQ obtained for metformin and alogliptin by the proposed method in plasma was 5.936 and 1.983 µg/mL respectively. The retention times obtained for metformin and alogliptin in plasma were 2.734 and 4.451 respectively. Quantitative linearity of drugs in plasma was obeyed in the concentration range of 300-700 µg/mL for metformin and 7.5-17.5 µg/mL for alogliptin respectively. The relevant regression equations were $y=1192x-38173$ for metformin ($r^2=0.997$) and $y=2802x-1113$ for alogliptin ($r^2=0.998$) (where $y$ is the peak area and $x$ is the concentration of metformin and alogliptin (µg/mL)). The intra-day and inter-day drugs variations in plasma by the proposed method showed percentage relative standard deviation were less than 2%, indicating that the method is precise. The corresponding mean recoveries of the drugs in plasma were 98.40-100.17%. This reveals that the method is quite accurate. The percentage relative standard deviation obtained for the drugs spiked in plasma for stability studies were less than 2%.

Conclusion

The proposed HPLC method was found to be simple, precise, accurate and sensitive for the simultaneous determination of metformin and alogliptin. The method was validated as per ICH guidelines and all the parameters met within the acceptance criteria. Applicability of this method for simultaneous estimation of metformin and alogliptin in plasma was confirmed.

Acknowledgements

The authors are thankful to M/s Pharma Train, Hyderabad for providing reference samples of metformin and alogliptin and processed plasma.
References

1. Medicinenet (2015) Diabetes (Type 1 and Type 2). www.medicinenet.com/ diabetes_mellitus/article.htm. Accessed on: August 2015.

2. Medicalnewstoday (2015) Diabetes: Symptoms, Causes and Treatments. http://www.medicalnewstoday.com/info/diabetes. Accessed on: August 2015.

3. Wikipedia (2015) Alogliptin. http://en.wikipedia.org/wiki/aogliptin. Accessed on: August 2015.

4. Drugbank (2015) http://www.drugbank.ca/drugs. Accessed on: August 2015.

5. Druginformation (2015) http://www.druginformation.com/. Accessed on: August 2015.

6. Rlist (2015) http://www.rlist.com/resina-drug/indications-dosage. Accessed on: August 2015.

7. Wikipedia (2015) Metformin. http://en.wikipedia.org/wiki/metformin. Accessed on: August 2015.

8. Rlist (2015) http://www.rlist.com/fortamet-drug.htm. Accessed on: August 2015.

9. Khan G, Agrawal YP, Sabarwal N, Jain A, Gupta A K (2011) Simultaneous Estimation of Metformin and Sitagliptin In tablet dosage form. Asian J Biochem Pharma Res 1: 352-358.

10. Patil SS, Bonde C G (2009) Development and Validation of analytical method for simultaneous estimation of Gilbenclamide and Metformin HCl in Bulk and Tablets using UV visible spectroscopy. Int J Chem Tech Res 1: 62-69.

11. Ramzia EJ -Bagary, Ehab EF, Bassam AM (2011) Spectrofluorometric and Spectrophotometric methods for the determination of Sitagliptin in binary mixture with Metformin and ternary mixture with Metformin and Sitagliptin Alkaline Degradation Product. Int J Biomed Sci 7: 62-69.

12. Hassassad SM, Mahmoud WH, Elmosallamy MA, Othman AH (1999) Determination of Metformin in pharmaceutical preparations using potentiometry, spectrophotometry and UV-visible spectrophotometry. Anal Chimica 378: 299-311.

13. Ravi PP, Sastry BS, Rajendra PY, Appala RN (2011) Simultaneous Estimation of Metformin HCl and Sitagliptin Phosphate in tablet dosage forms by RP-HPLC. Res J Pharm Tech 4: 646-649.

14. Shyamala M, Mohideen S, Satyanarayana T, Narasimha R, Suresh K (2011) Validated RP-HPLC for simultaneous estimation of Sitagliptin phosphate and Metformin in hydrochloride in tablet dosage form. American J Pharm Tech Res 1: 93-101.

15. Freddy HH, Dhamrendra VL (2010) Simultaneous estimation of Metformin hydrochloride, rosiglitazone and pioglitazone hydrochloride in the tablets dosage form. Int J App Bio Pharm Téc 1: 1000-1005.

16. Aburuz S, Millership J, McLaren J (2005) The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimepiride in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 817: 277-286.

17. Al-Rimawi F (2009) Development and validation of an analytical method for metformin hydrochloride and its related compound (1-cyanojugandine) in tablet formulations by HPLC-UV. Tablanta 79: 1368-1371.

18. Lakshmi KS, Rajesh T, Sharma S, Lakshmi S (2009) Development and Validation of Liquid Chromatographic and UV Derivative Spectrophotometric Methods for the Determination of Metformin, Pioglitazone and Glimipiride in Pharmaceutical Formulations. Der Pharma Chemica 1: 238-246.

19. Jain D, Jain S, Jain D, Amin M (2008) Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and gliclazide by RP-HPLC in tablet formulation. J Chromatogr Sci 46: 501-504.

20. Lakshmi KS, Rajesh T, Sharma S (2009) Simultaneous determination of Metformin and pioglitazone by reversed phase HPLC in pharmaceutical dosage forms. Int J Pharm Pharm Sci 1: 162-166.

21. Alexandar S, Diwedi R, Chandrasekar M (2010) A RP-HPLC method for simultaneous estimation of Metformin and pioglitazone in pharmaceutical formulation. Res Pharm Bio Chem Sci 1: 858-866.

22. Florentin T, Monica A (2007) Specificity of an analytical HPLC assay method of Metformin hydrochloride. Revue Roumaine Chimie 52: 603-609.

23. Pawar S, Meshram G, Jadhav R, Bansal Y (2010) Simultaneous determination of Glimipiride and Metformin hydrochloride impurities in sustained release pharmaceutical drug product by HPLC. Der Pharma Chemica 2: 157-168.

24. Zeng W, Xu Y, Constantzer M, Woolf EJ (2010) Determination of sitagliptin human plasma using protein precipitation and tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 1817-1823.

25. Zeng W, Musson DG, Fisher AL, Chen L, Schwartz MS, et al. (2008) Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry. J Pharm Biomed Anal 46: 534-542.

26. Georgita C, Albu F, David V, Medvedovici A (2007) Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 864: 211-218.

27. Nirogi R, Kandikere V, Mudigonda K, Komameni P, Aleti R (2008) Sensitive liquid chromatography tandem mass spectrometry method for the quantification of Sitagliptin, a DPP-4 inhibitor, in human plasma using liquid–liquid extraction. Biomed Chromatogr 22: 214-222.

28. Havele S, Dhaneshwar S (2010) Estimation of Metformin in Bulk Drug and in Formulation by HPTLC. J Nanomedic Nanotechnol 1: 102.

29. Ashutosh KS, Manidipa D, Seshagiri RJVLN (2013) Simultaneous Estimation of Metformin Hydrochloride and Sitagliptin Phosphate Monohydrate in bulk as well as in Pharmaceutical formulation by RP-HPLC. AM J Pharm Tech Res 3: 556-575.

30. Ashutosh KS, Manidipa D, Seshagiri RJVLN (2013) Development of stability indicating RP-HPLC method for simultaneous estimation of Metformin Hydrochloride and Sitagliptin Phosphate Monohydrate in bulk as well as in Pharmaceutical Formulation. Der Pharmacia Sinica 4: 47-61.

31. Satya SG, Ashutosh KS, Saravanan J, Manidipa D, Gresheema V, et al. (2013) A new RP-HPLC method development for simultaneous estimation of metformin and alogliptin in bulk as well as in pharmaceutical formulation by using PDA detector. World Journal of Pharmacy and Pharmaceutical Sciences 2: 6720-6743.

32. Satya SG, Ashutosh KS, Saravanan J, Manidipa D, Gresheema V, et al. (2013) A new stability indicating RP-HPLC method development for simultaneous estimation of metformin and alogliptin in bulk as well as in pharmaceutical formulation by using PDA detector. Indo American Journal of Pharmaceutical Research 3: 9222-9241.

33. Validation of analytical procedure: Methodology Q2B, (1996) ICH Harmonized Tripartite Guidelines 1-8.

34. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonized tripartite guideline Validation of analytical procedures: Text and Methodology Q2 (R1) 6 November 1996.

35. Ravichandran V, Shalini S, Sundram KM, Harish R (2010) Validation of analytical methods – strategies & importance. Int J Pharmay and Pharm Sci 2: 18-22.

36. Tangri P, Rawat PS, Jakhmola V (2012) Validation: A Critical Parameter for Quality Control of Pharmaceuticals. Journal of Drug Delivery & Therapeutics 3: 34-40.

37. ICH, Validation of Pharmaceutical Procedures, Text and Methodology Q2 (R1) (2005) International conference on Harmonization, IFPMA, Geneva, Switzerland.

38. ICH harmonized tripartite guideline. Impurities in New Drug products Q3B (R2) current step 4 versions dated 2 June 2006.

39. International Conference on Harmonization, ICH Q1 A(R2), Stability Testing of New Drug Substances and Products 2003.